,%20consisting%20of%20L-serine,%20N-acetyl-L-cysteine%20(NAC),%20NR,%20and%20L-carnitine%20tartrate%20for%20the%20treatment%20of%20patients%20...){kind=link}
Nicotinamide Riboside Supplementation Combined with Other Nutrients Accelerates Recovery in COVID-19 Patients: Clinical Findings
Objectives
To investigate supplementation of the combined metabolic activators (CMA), consisting of L-serine, N-acetyl-L-cysteine (NAC), NR, and L-carnitine tartrate for the treatment of patients with COVID-19.
Journal
Advanced Science
Key Outcomes
- After 14 days, CMA supplementation significantly reduced recovery time compared to placebo group in phase II (6.6 vs 9.3 days, respectively), as well as in phase III (5.7 vs. 9.2 days, respectively).
- CMA supplementation also improved liver health and markers of inflammation in COVID-19 patients.
Duration
2 weeks
Dose
2000 mg*
*Combined metabolic activators” or “CMA,” in combination with hydroxychloroquine (HCQ) or favipiravir (FP) for the treatment of patients with COVID-19. The CMA was administered twice per day for 14 days, and each dose consisted of 1 g NR, 3.73 g L-carnitine tartrate, 12.35 g serine, and 2.55 g N-acetyl-L-cysteine.
Study Design
Phase II: Randomized, open-label, placebo-controlled study in 93 patients & Phase III: Randomized, double-blind, placebo-controlled study in 309 COVID-19 patients